Fascin expression is inversely correlated with breast cancer metastasis suppressor 1 and predicts a worse survival outcome in node-negative breast cancer patients

被引:17
|
作者
Lee, Hye Jin [1 ]
An, Hee Jung [1 ]
Kim, Tae Hoen [1 ]
Kim, Gwangil [1 ]
Kang, Haeyoun [1 ]
Heo, Jin Hyung [1 ]
Kwon, Ah-Young [1 ]
Kim, Sewha [1 ]
机构
[1] CHA Univ, CHA Bundang Med Ctr, Dept Pathol, 59 Yatap Ro, Seongnam Si 13496, Gyeonggi Do, South Korea
来源
JOURNAL OF CANCER | 2017年 / 8卷 / 16期
关键词
breast cancer; fascin; breast cancer metastasis suppressor 1; immunohistochemistry; AGGRESSIVE CLINICAL-COURSE; CARCINOMA METASTASIS; ACTIN CYTOSKELETON; OVARIAN-CARCINOMA; BRMS1; PROTEIN; CELLS; MIGRATION; MOTILITY; MARKER;
D O I
10.7150/jca.22046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Fascin is an actin-bundling protein that promotes cancer cell migration and invasion. By contrast, breast cancer metastasis suppressor 1 (BRMS1) inhibits cancer metastasis by targeting multiple steps of the metastatic cascade. We evaluated whether expression patterns of fascin and BRMS1 correlate with clinicopathological features and patient outcome. Methods: Immunohistochemistry for fascin and BRMS1 was performed using a tissue microarray constructed from 183 human breast cancer tissues. Fascin expression determined by the proportion of stained tumor cells (0: 0-5%, 1: 6-25%, 2: 26-50%, 3: 51-75%, or 4: >75%) and staining intensity (0: negative, 1: weak, 2: moderate, or 3: strong) were multiplied and defined as negative (0-3) or positive (4-12). BRMS1 expression was scored separately based on nuclear and cytoplasmic staining intensity (0: negative, 1: weak, 2: moderate, 3: strong). We obtained the BRMS1 H score by summing the nuclear and cytoplasmic scores and defined it as negative (0-2) or positive (3-6). Results: Expression of BRMS1 showed a significant inverse correlation with that of fascin. Fascin(+) tumors were significantly associated with no lymph node metastasis, higher histological and higher nuclear grade, ER/PR/HER2 negativity, and triple-negative subtype (all ps < 0.05). These clinicopathological differences showed the same trend in a comparison of fascin(-)/BRMS1(+) and fascin(+)/BRMS1(-) tumors. Negative or weak BRMS1 cytoplasmic expression was significantly associated with shorter disease-free survival (DFS; p = 0.043). Fascin positivity was significantly associated with shorter DFS (p = 0.005) and overall survival (p = 0.020) when analyses were confined to node-negative patients. Conclusions: This study confirms an inverse correlation between expression of fascin and expression of BRMS1 using a quite large cohort of human breast cancer tissues. Fascin alone or combined with BRMS1 was a worse prognostic marker, particularly in node-negative breast cancer patients.
引用
收藏
页码:3122 / 3129
页数:8
相关论文
共 50 条
  • [21] Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis
    Chapman, JAW
    Lickley, HLA
    Trudeau, ME
    Hanna, WM
    Kahn, HJ
    Murray, D
    Sawka, CA
    Mobbs, BG
    McCready, DR
    Pritchard, KI
    BREAST JOURNAL, 2006, 12 (01): : 37 - 47
  • [22] Intramammary lymph node metastasis predicts poorer survival in breast cancer patients
    Hogan, Brian V.
    Peter, Mark B.
    Shenoy, Hrishikesh
    Horgan, Kieran
    Shaaban, Abeer
    SURGICAL ONCOLOGY-OXFORD, 2010, 19 (01): : 11 - 16
  • [23] Fascin expression predicts lymph node metastasis and worse survival in small intestinal carcinoma
    Gu, Mi Jin
    Kim, Jung Yeon
    Park, Jae Bok
    PATHOLOGY, 2014, 46 (01) : 21 - 24
  • [24] Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype
    Theriault, Rachel L.
    Litton, Jennifer K.
    Mittendorf, Elizabeth A.
    Chen, Huiqin
    Meric-Bernstam, Funda
    Chavez-MacGregor, Mariana
    Morrow, Phuong K.
    Woodward, Wendy A.
    Sahin, Aysegul
    Hortobagyi, Gabriel N.
    Gonzalez-Angulo, Ana M.
    CLINICAL BREAST CANCER, 2011, 11 (05) : 325 - 331
  • [25] Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer
    Ricciardelli, C
    Brooks, JH
    Suwiwat, S
    Sakko, AJ
    Mayne, K
    Raymond, WA
    Seshadri, R
    LeBaron, RG
    Horsfall, DJ
    CLINICAL CANCER RESEARCH, 2002, 8 (04) : 1054 - 1060
  • [26] Cyclin E2 mRNA expression and metastasis-free survival in untreated node-negative breast cancer patients.
    Schmidt, M
    Glawatz, C
    Gehrmann, MC
    Puhl, A
    von Toerne, C
    Steiner, E
    Boehm, D
    Koelbl, H
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S140 - S141
  • [27] DEAD box 1 (DDX1) expression predicts for local control and overall survival in early stage, node-negative breast cancer
    Taunk, Neil K.
    Goyal, Sharad
    Wu, Hao
    Moran, Meena S.
    Chen, Sining
    Haffty, Bruce G.
    CANCER, 2012, 118 (04) : 888 - 898
  • [28] JAG1 expression, associated with basal phenotype, predicts recurrence in lymph node-negative breast cancer
    Reedijk, M.
    Pinnaduwage, D.
    Dickson, B. C.
    Mulligan, A. M.
    Zhang, H.
    Bull, S. B.
    O'Malley, F. P.
    Egan, S. E.
    Andrulis, I. L.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 : 25 - 25
  • [29] Cyclin A overexpression and survival in node-negative (N-) breast cancer patients.
    Baldini, E
    Camerini, A
    Prochilo, T
    Pasqualetti, F
    Orlandini, C
    Capodanno, A
    Salvadori, B
    Collecchi, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 26S - 26S
  • [30] Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer
    Heimann, R
    Ferguson, D
    Powers, C
    Recant, WM
    Weichselbaum, RR
    Hellman, S
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (23): : 1764 - 1769